Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?

The widespread use of drugs that bind diffusible vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular age-related macular degeneration (AMD). The pivotal ranibizumab and aflibercept registration trials featured monthly intravitreal injections for 12 months, durin...

Descripción completa

Detalles Bibliográficos
Autor principal: Stewart, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470218/
https://www.ncbi.nlm.nih.gov/pubmed/26239466
http://dx.doi.org/10.3390/jcm4051079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470218/
https://www.ncbi.nlm.nih.gov/pubmed/26239466
http://dx.doi.org/10.3390/jcm4051079

Ejemplares similares